Illustrative only
GeographyUS
Addressable patients60,000
Probability of success, base28%
Potential launchQ2 ’30
Peak sales · Base case$180m
Risk-adjusted peak sales$50m
Development spend, next 12 months4%
Market attractiveness
- Market size2 / 5
- Unmet need3.5 / 5
- Competitive headroom2 / 5
- Pricing potential4 / 5
Why it sits where it does
A well-priced specialty indication with the nearest Phase II readout in the portfolio.
0–5 = attractiveness. A crowded market or a high bar scores low.
Assessment summary
Next decision
Phase II readout 2027 – PoS 28% → 55% if positive.
The nine modules behind this summary are built out on Heart failure (HFrEF) in this preview.
Open the HFrEF workspace